119 related articles for article (PubMed ID: 9173000)
1. [Pharmacological studies of BX661A. 5-[4-(2-carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (1). Therapeutic effects on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) model in rats].
Kimura I; Nagahama S; Kawasaki M; Kataoka M; Sato M
Nihon Yakurigaku Zasshi; 1997 Feb; 109(2):85-94. PubMed ID: 9173000
[TBL] [Abstract][Full Text] [Related]
2. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
3. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
[TBL] [Abstract][Full Text] [Related]
4. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
[TBL] [Abstract][Full Text] [Related]
5. [Study on the experimental ulcerative colitis (UC) model induced by dextran sulfate sodium (DSS) in rats (3)].
Kimura I; Nagahama S; Kawasaki M; Kataoka M; Sato M
Nihon Yakurigaku Zasshi; 1996 Nov; 108(5):259-66. PubMed ID: 8974086
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Kane SV; Bjorkman DJ
Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
[TBL] [Abstract][Full Text] [Related]
7. [Study on the experimental ulcerative colitis (UC) model induced by dextran sulfate sodium (DSS) in rats (2)].
Kimura I; Nagahama S; Kawasaki M; Kamiya A; Kataoka M
Nihon Yakurigaku Zasshi; 1995 Mar; 105(3):145-52. PubMed ID: 7721192
[TBL] [Abstract][Full Text] [Related]
8. Review article: balsalazide therapy in ulcerative colitis.
Ragunath K; Williams JG
Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
Hanauer SB
Am J Gastroenterol; 2003 Mar; 98(3):697-8. PubMed ID: 12650813
[No Abstract] [Full Text] [Related]
10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
11. Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice.
Li YH; Zhang M; Xiao HT; Fu HB; Ho A; Lin CY; Huang Y; Lin G; Bian ZX
PLoS One; 2015; 10(12):e0144101. PubMed ID: 26642326
[TBL] [Abstract][Full Text] [Related]
12. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
Jo Y; Matsumoto T; Iida M
Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory effects of Brucea javanica oil emulsion by suppressing NF-κB activation on dextran sulfate sodium-induced ulcerative colitis in mice.
Huang YF; Zhou JT; Qu C; Dou YX; Huang QH; Lin ZX; Xian YF; Xie JH; Xie YL; Lai XP; Su ZR
J Ethnopharmacol; 2017 Feb; 198():389-398. PubMed ID: 28119098
[TBL] [Abstract][Full Text] [Related]
14. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.
Nakashima T; Maeda T; Nagamoto H; Kumakura T; Takai M; Mori T
Dig Dis Sci; 2005 Oct; 50 Suppl 1():S124-31. PubMed ID: 16184415
[TBL] [Abstract][Full Text] [Related]
15. Balsalazide disodium.
Am J Health Syst Pharm; 2002 Jan; 59(1):27. PubMed ID: 11813462
[No Abstract] [Full Text] [Related]
16. [Pharmacological bases of therapy with 5-ASA].
Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
[No Abstract] [Full Text] [Related]
17. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
18. Will the real 5-aminosalicylic acid please stand up?
Regueiro MD
Inflamm Bowel Dis; 1999 May; 5(2):147-8. PubMed ID: 10338387
[No Abstract] [Full Text] [Related]
19. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
20. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.
McIntyre PB; Rodrigues CA; Lennard-Jones JE; Barrison IG; Walker JG; Baron JH; Thornton PC
Aliment Pharmacol Ther; 1988 Jun; 2(3):237-43. PubMed ID: 2908755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
